IL6R and temporal arteritis: Sarilumab, another anti-IL6R monoclonal antibody, recently shown to be effective in a phase 3 study and thus approved by the FDA for the treatment of PMR [148] is also under investigation for GCA treatment (ClinicalTrials ID: NCT03600805).